Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NC › Huntersville › NPI 1770741654

Unity Healthcare

Unity Healthcare was paid $2.09M by Medicaid between Dec 2019 and Nov 2024, across 7 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 65% of everything it billed.

33Billing provider infoUNITY HEALTHCARE
HUNTERSVILLE, NC 28078
33aNPI1770741654assigned 05/28/2008
28Total paid$2.09M
24GClaims21,403
24DCodes billed7
24AFirst – last monthDec 2019 – Nov 2024
Box 24A · Dates of service

Paid by month

$0$50K$100K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201965$8K
20202,312$264K
20215,160$556K
20225,440$519K
20234,818$440K
2024incomplete3,608$302K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 65% 10,349 3,638 $1.35M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 32% 10,450 3,687 $658K
99236 Prolong inpt eval add15 m 2.7% 371 238 $56K
99244 Office or other outpatient consultation, moderate to high complexity 1.1% 173 117 $23K
90791 Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation <1% 18 17 $1K
99442 <1% 26 15 $218.45
96127 <1% 16 14 $59.50

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialDIAZ, TANYA (ACCOUNT EXECUTIVE)